Bemarituzumab 是一种针对FGFR2b(一种 FGF 受体) 的首创的人源化 IgG1 单克隆抗体。Bemarituzumab 阻止成纤维细胞生长因子结合和激活 FGFR2b。Bemarituzumab 具有用于癌症研究的潜力。
| 生物活性 | Bemarituzumab is a first-in-class, humanizedIgG1monoclonal antibody againstFGFR2b(a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential forcancerresearch[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com